Lidocaína B. Braun (Lidocaine Hydrochloride)

Lidocaine blocks voltage‑gated sodium channels on neuronal membranes, stabilising them in an inactive state. By preventing sodium influx, the drug stops the depolarisation necessary for nerve impulse generation and propagation, resulting in a reversible loss of sensation in the area where it is administered.

The appropriate dose of Lidocaína B. Braun is determined by the prescribing clinician based on the specific procedure, the site of administration, patient age, weight, and overall health status. No standard dosing is provided here; the prescriber tailors the amount to achieve effective anesthesia while minimising toxicity.

Safety data for lidocaine in pregnancy and lactation are limited. Use is generally reserved for situations where the benefit outweighs potential risk, and the decision should be made by a qualified healthcare professional. Breastfeeding mothers should consult their physician, as lidocaine can be excreted in small amounts in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Lidocaine has a rapid onset of action (1–3 minutes) and a moderate duration (30–120 minutes), whereas bupivacaine has a slower onset but a longer duration (up to several hours). Lidocaine is often chosen for procedures requiring quick recovery, while bupivacaine is preferred for prolonged analgesia. Both share similar mechanisms but differ in potency and toxicity profiles.

Lidocaína B. Braun should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from direct sunlight, moisture and extreme temperature fluctuations. Do not freeze the solution, and keep it out of reach of children.

The product is supplied as a sterile solution for injection and is administered by a qualified healthcare professional via epidural, infiltration or intradermal routes. The clinician selects the appropriate needle size, injects the solution slowly, and monitors the patient for any immediate adverse reactions.

Serious risks include central nervous system toxicity such as seizures, and cardiovascular toxicity manifesting as arrhythmias, severe hypotension or cardiac arrest. These events are more likely with high plasma concentrations, accidental intravascular injection, or when combined with interacting medications.

Patients with a known hypersensitivity to lidocaine or other amide‑type local anesthetics should avoid this product. Caution is also advised for individuals with severe hepatic impairment, significant cardiac conduction disorders, or those taking medications that markedly increase lidocaine plasma levels.